Mostrar el registro sencillo del ítem
dc.contributor.author | Rathore, Sawai Singh | |
dc.contributor.author | Hussain, Nabeel | |
dc.contributor.author | Manju, Ade Harrison | |
dc.contributor.author | Wen, Qingqing | |
dc.contributor.author | Tousif, Sohaib | |
dc.contributor.author | Avendano-Capriles, Camilo Andres | |
dc.contributor.author | Hernandez-Woodbine, Maria Jose | |
dc.contributor.author | Rojas, Gianpier Alonzo | |
dc.contributor.author | Vatsavayi, Priyanka | |
dc.contributor.author | Tera, Chenna Reddy | |
dc.contributor.author | Ali, Muhammad Adnan | |
dc.contributor.author | Singh, Romil | |
dc.contributor.author | Saleemi, Shayan | |
dc.contributor.author | Patel, Deep Manojkumar | |
dc.date.accessioned | 2021-10-04T23:01:00Z | |
dc.date.available | 2021-10-04T23:01:00Z | |
dc.date.issued | 2021 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/9873 | |
dc.description.abstract | Observational studies indicate that pleural effusion has an association with risk and the clinical prognosis of COVID-19 disease; however, the available literature on this area is inconsistent. The objective of this systematic review and meta-analysis is to evaluate the correlation between COVID-19 disease and pleural effusion. A rigorous literature search was conducted using multiple databases. All eligible observational studies were included from around the globe. The pooled prevalence and associated 95% confidence interval (CI) were calculated using the random effect model. Mantel-Haenszel odds ratios were produced to report overall effect size using random effect models for severity and mortality outcomes. Funnel plots, Egger regression tests, and Begg-Mazumdar's rank correlation test were used to appraise publication bias. Data from 23 studies including 6234 COVID-19 patients was obtained. The overall prevalence of pleural effusion in COVID-19 patients was 9.55% (95% CI, I2 =92%). Our findings also indicated that the presence of pleural effusions associated with increased risk of severity of disease(OR=5.08, 95% CI 3.14-8.22, I2 =77.4%) and mortality due to illness(OR=4.53, 95% CI 2.16-9.49, I2 =66%) compared with patients without pleural effusion. Sensitivity analyses illustrated a similar effect size while decreasing the heterogeneity. No significant publication bias was evident in the meta-analysis. The presence of pleural effusion can assist as a prognostic factor to evaluate the risk of worse outcomes in COVID-19 patients hence, it is recommended that hospitalized COVID-19 patients with pleural effusion should be managed on an early basis | en_US |
dc.language.iso | eng | |
dc.publisher | Wiley | |
dc.relation.ispartofseries | Journal of Medical Virology | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | COVID-19 | en_US |
dc.subject | pleural effusion | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | X-ray computed tomography | en_US |
dc.subject | viral | en_US |
dc.subject | pleural disease | en_US |
dc.title | Prevalence and clinical outcomes of pleural effusion in COVID-19 patients: A systematic review and meta-analysis. | en_US |
dc.type | info:eu-repo/semantics/review | |
dc.identifier.doi | https://doi.org/10.1002/jmv.27301 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#1.06.02 | |
dc.relation.issn | 1096-9071 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |